{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T02:10:05Z","timestamp":1735438205960,"version":"3.32.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,28]]},"DOI":"10.7759\/cureus.76543","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T01:57:41Z","timestamp":1735437461000},"source":"Crossref","is-referenced-by-count":0,"title":["Dosimetric Planning Comparison for Left Ventricle Avoidance in Non-small Cell Lung Cancer Radiotherapy"],"prefix":"10.7759","author":[{"given":"Oi-Wai","family":"Chau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart","family":"Gaede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks LB","year":"2010","unstructured":"Marks LB, Bentzen SM, Deasy JO, et al.. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010, 76:S70-6. 10.1016\/j.ijrobp.2009.06.091","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.12.044","article-title":"Is the importance of heart dose overstated in the treatment of non-small cell lung cancer? A systematic review of the literature","volume":"104","author":"Zhang TW","year":"2019","unstructured":"Zhang TW, Snir J, Boldt RG, et al.. Is the importance of heart dose overstated in the treatment of non-small cell lung cancer? A systematic review of the literature. Int J Radiat Oncol Biol Phys. 2019, 104:582-9. 10.1016\/j.ijrobp.2018.12.044","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.0229","article-title":"Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy","volume":"35","author":"Wang K","year":"2017","unstructured":"Wang K, Eblan MJ, Deal AM, et al.. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017, 35:1387-94. 10.1200\/JCO.2016.70.0229","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley JD","year":"2020","unstructured":"Bradley JD, Hu C, Komaki RR, et al.. Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2020, 38:706-14. 10.1200\/JCO.19.01162","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2010.504736","article-title":"Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer","volume":"49","author":"Schytte T","year":"2010","unstructured":"Schytte T, Hansen O, Stolberg-Rohr T, Brink C. Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer. Acta Oncol. 2010, 49:1058-60. 10.3109\/0284186X.2010.504736","journal-title":"Acta Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19032","article-title":"Combing NLR, V20 and mean lung dose to predict radiation induced lung injury in patients with lung cancer treated with intensity modulated radiation therapy and chemotherapy","volume":"8","author":"Pan WY","year":"2017","unstructured":"Pan WY, Bian C, Zou GL, Zhang CY, Hai P, Zhao R, Wang YY. Combing NLR, V20 and mean lung dose to predict radiation induced lung injury in patients with lung cancer treated with intensity modulated radiation therapy and chemotherapy. Oncotarget. 2017, 8:81387-93. 10.18632\/oncotarget.19032","journal-title":"Oncotarget"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.01.051","article-title":"Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis","volume":"65","author":"Kong FM","year":"2006","unstructured":"Kong FM, Hayman JA, Griffith KA, et al.. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys. 2006, 65:1075-86. 10.1016\/j.ijrobp.2006.01.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley JD","year":"2015","unstructured":"Bradley JD, Paulus R, Komaki R, et al.. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015, 16:187-99. 10.1016\/S1470-2045(14)71207-0","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.09.134","article-title":"Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer","volume":"12","author":"Speirs CK","year":"2017","unstructured":"Speirs CK, DeWees TA, Rehman S, et al.. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer. J Thorac Oncol. 2017, 12:293-301. 10.1016\/j.jtho.2016.09.134","journal-title":"J Thorac Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.03.024","article-title":"Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy","volume":"120","author":"Lee CC","year":"2018","unstructured":"Lee CC, Zheng H, Soon YY, et al.. Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy. Lung Cancer. 2018, 120:54-9. 10.1016\/j.lungcan.2018.03.024","journal-title":"Lung Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00001","article-title":"Results of a single institution experience with dose-escalated chemoradiation for locally advanced unresectable non-small cell lung cancer","volume":"7","author":"Bernard ME","year":"2017","unstructured":"Bernard ME, Glaser SM, Gill BS, et al.. Results of a single institution experience with dose-escalated chemoradiation for locally advanced unresectable non-small cell lung cancer. Front Oncol. 2017, 7:1. 10.3389\/fonc.2017.00001","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6142","article-title":"Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer","volume":"35","author":"Dess RT","year":"2017","unstructured":"Dess RT, Sun Y, Matuszak MM, et al.. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol. 2017, 35:1395-402. 10.1200\/JCO.2016.71.6142","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01824-3","article-title":"Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer","volume":"16","author":"Turtle L","year":"2021","unstructured":"Turtle L, Bhalla N, Willett A, et al.. Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer. Radiat Oncol. 2021, 16:95. 10.1186\/s13014-021-01824-3","journal-title":"Radiat Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.05.007","article-title":"Exposure of the heart in lung cancer radiation therapy: a systematic review of heart doses published during 2013 to 2020","volume":"172","author":"Kearney M","year":"2022","unstructured":"Kearney M, Keys M, Faivre-Finn C, Wang Z, Aznar MC, Duane F. Exposure of the heart in lung cancer radiation therapy: a systematic review of heart doses published during 2013 to 2020. Radiother Oncol. 2022, 172:118-25. 10.1016\/j.radonc.2022.05.007","journal-title":"Radiother Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.05.014","article-title":"Dosimetric predictors of cardiotoxicity in thoracic radiotherapy for lung cancer","volume":"20","author":"Borkenhagen JF","year":"2019","unstructured":"Borkenhagen JF, Bergom C, Rapp CT, Klawikowski SJ, Rein LE, Gore EM. Dosimetric predictors of cardiotoxicity in thoracic radiotherapy for lung cancer. Clin Lung Cancer. 2019, 20:435-41. 10.1016\/j.cllc.2019.05.014","journal-title":"Clin Lung Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110005","article-title":"Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation","volume":"190","author":"Yegya-Raman N","year":"2024","unstructured":"Yegya-Raman N, Ho Lee S, Friedes C, et al.. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. Radiother Oncol. 2024, 190:110005. 10.1016\/j.radonc.2023.110005","journal-title":"Radiother Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/327802-dosimetric-planning-comparison-for-left-ventricle-avoidance-in-non-small-cell-lung-cancer-radiotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T01:57:42Z","timestamp":1735437462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/327802-dosimetric-planning-comparison-for-left-ventricle-avoidance-in-non-small-cell-lung-cancer-radiotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.76543","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,28]]}}}